Development of an ELISA for sPSP94 and utility of the sPSP94/sPSA ratio as a diagnostic indicator to differentiate between benign prostatic hyperplasia and prostate cancer
| Autor: | Jayesh V. Dhabalia, Dhanashree D. Jagtap, Sucheta P Dandekar, Smita D. Mahale, Meena Desai, M. I. Khatkhatay, Anand M. Varadkar, Swapna S. Desai, Deepa R Mhatre, Hemant B. Tongaonkar |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Adult
Male Pathology medicine.medical_specialty Clinical Biochemistry Urology Prostatic Hyperplasia Enzyme-Linked Immunosorbent Assay urologic and male genital diseases Biochemistry Cohort Studies Diagnosis Differential Prostate cancer Prostate Predictive Value of Tests Biopsy Medicine Humans In patient medicine.diagnostic_test business.industry Biochemistry (medical) Area under the curve Diagnostic test Prostatic Neoplasms Prostatic Secretory Proteins General Medicine Hyperplasia Middle Aged Prostate-Specific Antigen medicine.disease medicine.anatomical_structure Decision curve analysis Case-Control Studies business Biomarkers Blood Chemical Analysis |
| Zdroj: | Clinica chimica acta; international journal of clinical chemistry. 436 |
| ISSN: | 1873-3492 |
| Popis: | Background The serum PSA (sPSA) test has low specificity for prostate cancer (PCa), since sPSA also rises in benign prostatic hyperplasia (BPH). Serum PSP94 (sPSP94), a major secreted prostate protein, is indicated as a PCa marker. The potential of sPSP94 and sPSA in conjunction with each other to improve specificity of diagnostic test for PCa needs to be evaluated. Methods PCa patients (n = 33), BPH patients (n = 44) and healthy controls (n = 50) were recruited. A serum-based sandwich ELISA was developed to measure sPSP94 concentrations. Utility of sPSP94 in improving specificity of sPSA test was evaluated by studying sPSP94/sPSA ratios of study participants. Results Considerable decrease in overlap among sPSP94/sPSA ratio values of BPH and PCa patients was observed, as compared to sPSP94 or sPSA alone. For differentiating between BPH and PCa patients, this ratio had a maximum area under the curve (AUC) of 0.859 (P = 0.0132) and had a comparable sensitivity (90.91%) to sPSA with an increased specificity of 70.45%. Further, decision curve analysis (DCA) showed that sPSP94/sPSA ratio had a superior net benefit in identifying PCa, in patients opting for biopsy. Conclusion The sPSP94/sPSA ratio can be a better differentiating marker between BPH and PCa, than sPSP94 or sPSA alone. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect